Zobrazeno 1 - 8
of 8
pro vyhledávání: '"5 aza 2' deoxycytidine"'
Publikováno v:
Cancer letters
Cancer Lett.
Cancer Lett.
The purpose of this work is to determine the molecular mechanisms underlying tamoxifen resistance. We show here that ER-β is epigenetically silenced in a cell line with acquired tamoxifen resistance (MCF-7/TAM-R) and this could be reversed by 5-AZA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26b9046cf7b23e8e6db6523b75919379
https://doi.org/10.1016/j.canlet.2013.05.031
https://doi.org/10.1016/j.canlet.2013.05.031
Autor:
Orta Vázquez, Manuel Luis, Calderón Montaño, José Manuel, Domínguez García, Inmaculada, Burgos Morón, Estefanía, Pastor Carrillo, Nuria María, López Lázaro, Miguel, Helleday, Thomas
Publikováno v:
idUS. Depósito de Investigación de la Universidad de Sevilla
instname
instname
Decitabine (5-aza-21-deoxycytidine, 5-azadC) is used in the treatment of Myelodysplatic syndrome (MDS) and Acute Myeloid Leukemia (AML). Its mechanism of action is thought to involve reactivation of genes implicated in differentiation and transformat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a0f9838b53cbe4fd72099b5e869868d0
https://idus.us.es/handle/11441/41298
https://idus.us.es/handle/11441/41298
Autor:
Miguel López-Lázaro, Estefanía Burgos-Morón, José Manuel Calderón-Montaño, Nuria Pastor, Torkild Visnes, Manuel Luis Orta, Thomas Helleday, Cecilia E. Ström, Inmaculada Domínguez, Andreas Höglund
Publikováno v:
Nucleic Acids Research
Decitabine (5-aza-21-deoxycytidine, 5-azadC) is used in the treatment of Myelodysplatic syndrome (MDS) and Acute Myeloid Leukemia (AML). Its mechanism of action is thought to involve reactivation of genes implicated in differentiation and transformat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::878e4ac023f0eb92d0a2f513693abb7f
https://idus.us.es/xmlui/handle/11441/41298
https://idus.us.es/xmlui/handle/11441/41298
Objective: Epigenetic modulation of gene expression by DNA promoter methylation may contribute to acquired resistance to chemotherapy in cancer cells. Decitabine (5-aza-2'-deoxycytidine), a demethylating agent, may act synergistically with standard c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d900671fbd4dc813005ae482b0248145
http://hdl.handle.net/11452/33105
http://hdl.handle.net/11452/33105
Autor:
Napieralski, Rudolf, Colling, Christoph, Honert, Katja, Krueger, Achim, Schmitt, Manfred, Kiechle, Marion
Epigenetic drugs are promising add-ons to cancer treatment; still, adverse effects concerning tumour promotion have been reported occasionally. In this in vitro study, we investigated the effect of combination treatment of decitabine with anthracycli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______9458::d5f07f938755335165302641727b08d1
http://hdl.handle.net/11452/23937
http://hdl.handle.net/11452/23937
Autor:
Mehmet H. Koseoglu, Hulki Meltem Sönmez, Ekrem Muftuoglu, Gurhan Kadikoylu, Süleyman Demir, Orhan Ayyildiz, Zahit Bolaman
Publikováno v:
Haematologia. 32(1)
Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90932862c6640e3652355e3f72548f7
https://pubmed.ncbi.nlm.nih.gov/12243555
https://pubmed.ncbi.nlm.nih.gov/12243555
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.